Generic Invega Sustenna

At this time, patents and exclusivity rights prevent a generic Invega Sustenna (paliperidone palmitate) from being manufactured in the United States. The first patent is expected to expire in April 2013, which would be the earliest date that a generic version might become available. However, certain circumstances could delay this date, such as lawsuits or other patents for new uses of the medicine.

Can I Buy Generic Invega Sustenna?

Invega® Sustenna® (paliperidone palmitate) is a prescription medication used to treat schizophrenia. It comes as a long-acting monthly injection.
 
Invega Sustenna is manufactured by Janssen Pharmaceutica N.V. for Janssen Pharmaceuticals, Inc. It is protected by patents and exclusivity rights that prevent any generic Invega Sustenna from being manufactured in the United States.
 

When Will a Generic Version Be Available?

The first patent is set to expire in April 2013. This is the earliest predictable date that a generic version could become available.
 
However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for new Invega Sustenna uses. Once the patent expires, there may be several companies that manufacture a generic Invega Sustenna drug.
 

Is Paliperidone Palmitate a Generic Invega Sustenna?

No --
 paliperidone palmitate is the active ingredient in Invega Sustenna, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name." The generic name is different from a generic version of a medicine.
 
In order for there to be a generic version of a medicine, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.
Written by/reviewed by: Susan Lakey, PharmD, MPH, BCPP
Last reviewed by: Kristi Monson, PharmD
Other Articles in This eMedTV Presentation